On This Page
- Diagnosed and undiagnosed diabetes in the United States, all ages, 2010
- Diagnosed and undiagnosed diabetes among people aged 20 years or older, United States, 2010
- Diagnosed diabetes among people younger than 20 years of age, United States, 2010
- Racial and ethnic differences in diagnosed diabetes
- New cases of diagnosed diabetes among people aged 20 years or older, United States, 2010
- New cases of diagnosed diabetes among people younger than 20 years of age, United States, 2002–2005
- Prediabetes among people aged 20 years or older, United States, 2010
- Gestational diabetes in the United States
- Treatment of diabetes in the United States, 2007–2009
- Deaths among people with diabetes, United States, 2007
- Estimated diabetes costs in the United States, 2007
- Complications of diabetes in the United States
- Preventing diabetes complications
- What is diabetes?
- Prevention or delay of type 2 diabetes
2011 National Diabetes Fact Sheet
Return to the Table of Contents
Data Sources, Methods, and References for Estimates of Diabetes and Prediabetes
Attention:
A Major Change in Methods from the National Diabetes
Fact Sheet, 2007
In the National Diabetes Fact Sheet, 2011, we defined undiagnosed diabetes and prediabetes based on both fasting glucose and hemoglobin A1c (A1c) levels. This is in contrast to the National Diabetes Fact Sheet, 2007, that used fasting glucose levels only.
Diagnosed and undiagnosed diabetes in the United States, all ages, 2010
Methods:
The total number of people with diabetes is the sum of
the number of those aged 20 years or older with
diagnosed or undiagnosed diabetes and the number of
those younger than 20 years with diagnosed diabetes.
Detailed methods are available in the next section for
those aged 20 years or older and in the following
section for those younger than 20 years.
The total number of people with diagnosed diabetes in 2010 is the sum of the estimated numbers of those younger than 20 years and those aged 20 years or older with diagnosed diabetes.
The total number of people with undiagnosed diabetes in 2010 is the estimated number of those aged 20 years or older with undiagnosed diabetes. Estimates of undiagnosed diabetes for people younger than 20 years are not available.
These estimates have some variability due to the limits of the measurements and estimation procedures. The procedures assumed that percentages of adults with diabetes (diagnosed and undiagnosed) in 2010 were the same as they were in earlier time periods (e.g., 2005–2008), and that the percentages of adults with diabetes in the resident population are identical to those in the civilian, noninstitutionalized population. Deviations from these assumptions may result in over- or under-estimated numbers and percentages.
Diagnosed and undiagnosed diabetes among people aged 20 years or older, United States, 2010
Data source:
2005–2008 National Health And Nutrition Examination
Survey (NHANES), National Center for Health Statistics,
Centers for Disease Control and Prevention. Available at
http://www.cdc.gov/nchs/nhanes.htm.
Methods: The percentage of people aged 20 years or older with diabetes (diagnosed or undiagnosed) was obtained using the fasting subsample from the 2005–2008 NHANES data. People who self-reported having been told by a doctor or health professional that they had diabetes were classified as having diagnosed diabetes. Those without a history of diabetes but with a fasting plasma glucose greater than or equal to 126 mg/dl or an A1c level greater than or equal to 6.5% were classified as having undiagnosed diabetes. We used both fasting glucose and A1c levels to define undiagnosed diabetes because these are the tests most frequently used in clinical settings. These tests have limitations in identifying populations with undiagnosed diabetes and the implications of the age and race differences between groups in the estimates of undiagnosed diabetes are not known. Research is ongoing to ascertain the best use of laboratory blood tests to detect people who may have undiagnosed diabetes (see the National Glycosylated Standardization Program at http://www.ngsp.org/) and to improve the understanding of who has undiagnosed diabetes. The estimated percentage of diagnosed or undiagnosed diabetes was then applied to the 2010 U.S. resident population aged 20 years or older to derive the total number of adults with diabetes. These estimates were obtained by age groups (20–44 years, 45–64 years, and 65 years or older), by sex (men and women), and by race/ethnicity (non-Hispanic whites and non-Hispanic blacks). Information on the use of NHANES data to measure diabetes (including diagnosed and undiagnosed diabetes) is available from the following:
References:
Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD,
Li C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH,
Geiss LS. Full accounting of diabetes and prediabetes in
the U.S. population in 1988–1994 and 2005–2006. Diabetes
Care 2009;32:287–294.
Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, Bainbridge KE, Fradkin JE. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care 2010;33:562–568.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2011;34(Suppl. 1):S66–S68. Available at http://care.diabetesjournals.org/content/34/Supplement_1/S62.full.pdf+html.
Herman WH, Cohen RM. Hemoglobin A1c: teaching a new dog old tricks. Ann Intern Med 2010;152(12):815−817.
Diagnosed diabetes among people younger than 20 years of age, United States, 2010
Data sources:
2007–2009 National Health Interview Survey (NHIS),
National Center for Health Statistics, Centers for
Disease Control and Prevention. Available at
http://www.cdc.gov/nchs/nhis.htm.
U.S. Census Bureau, resident population estimates for 10/1/2010. Available at http://2010.census.gov/news/releases/operations/cb10-cn93.html.
Methods:
The percentage of people younger than 20 years with
diagnosed diabetes was obtained from the 2007–2009 NHIS
data. Information on diagnosed diabetes was obtained
from a knowledgeable adult family member residing in the
household for people younger than 18 years, and was
self-reported for people 18–19 years of age. The
estimate of diagnosed diabetes was applied to the 2010
U.S. resident population younger than 20 years to derive
the number of people with diagnosed diabetes in this age
group. Estimates of undiagnosed diabetes for people
younger than 20 years are not available.
Racial and ethnic differences in diagnosed diabetes
Data sources:
2007–2009 National Health Interview Survey (NHIS),
National Center for Health Statistics, Centers for
Disease Control and Prevention. Available at
http://www.cdc.gov/nchs/nhis.htm.
Indian Health Service (IHS), National Patient
Information Reporting System (NPIRS).
Methods:
With the exception of diagnosed diabetes among American
Indians and Alaska Natives (AIsANs),
race/ethnicity-specific estimates of diagnosed diabetes
were calculated using the 2007–2009 NHIS data. People
aged 20 years or older who self-reported having been
told by a doctor or health professional that they had
diabetes were classified as having diagnosed diabetes.
The percentages were age-adjusted — using age groups
20−39, 40−59, and ≥60 — by the direct method to the 2000
U.S. Census standard population. The estimate of
diagnosed diabetes for the Native Hawaiian and other
Pacific Islander population was not included because the
NHIS estimate for this group is considered unreliable
due to a small sample size.
Diagnosed diabetes among AIsANs was calculated using
2009 data from the IHS NPIRS. This system includes
patient registration and visit data that are received
directly from IHS facilities, tribally operated programs
and contract health systems. These health care
facilities serve about 1.9 million AIsANs who belong to
564 federally recognized tribes in 35 states. Data for
847,319 active patients aged 20 years or older were used
to calculate these estimates. Patients were considered
active if they received health care services at the IHS,
tribally operated programs, or contract health care
facilities during the preceding three years. Diabetes
cases among these patients were identified using the
International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) diagnostic
codes 250.0–250.93 from the patient visit data. Patients
were considered to have a diagnosis of diabetes if they
had at least two visits with the ICD 250 diagnosis code
reported during fiscal year 2009.
For many U.S. racial/ethnic minority populations, sufficient data are not available to derive total prevalence estimates of diabetes (diagnosed and undiagnosed). However, national estimates of diagnosed diabetes are available for some but not all minority groups. Resources to obtain data for minority groups at the state or local level include the Behavioral Risk Factor Surveillance System http://www.cdc.gov/brfss/stateinfo.htm and the California Health Interview Survey www.chis.ucla.edu. For more information on U.S. racial/ethnic minority groups, see the Census glossary http://factfinder.census.gov/home/en/epss/glossary_a.html.
New cases of diagnosed diabetes among people aged 20 years or older, United States, 2010
Data sources:
2007–2009 National Health Interview Survey (NHIS),
National Center for Health Statistics, Centers for
Disease Control and Prevention. Available at
http://www.cdc.gov/nchs/nhis.htm.
U.S. Census Bureau, resident population estimates for 10/1/2010. Available at http://2010.census.gov/news/releases/operations/cb10-cn93.html.
Methods:
The rate of new cases was calculated using 2007–2009
NHIS data on respondents' age at diagnosis and age at
interview. Adults who reported being diagnosed with
diabetes were asked at what age they were diagnosed. We
calculated the number of years since diagnosis of
diabetes for each person by subtracting the age at which
they were diagnosed from their current age. Adults who
had a value of zero were identified as having been
diagnosed with diabetes within the last year. In
addition, we assumed that half of the adults who had a
value of one were classified as having been diagnosed
with diabetes within the last year. To calculate the
rate, we used as the numerator the number of adults who
were diagnosed with diabetes within the last year, and
the denominator was the estimate of the adult
population, excluding adults who had been diagnosed with
diabetes for more than one year and adults who on the
NHIS were categorized as "refused," "don’t know," or who
had missing values on the diabetes status question. To
estimate the number of new cases of diabetes in each age
group in 2010, we applied the age-specific rates of new
cases to 2010 estimates of the U.S. resident population
without diabetes diagnosed in the past year.
New cases of diagnosed diabetes among people younger than 20 years of age, United States, 2002–2005
Data source:
SEARCH for Diabetes in Youth Study
Methods:
SEARCH is a multicenter observational study to examine
diabetes among children and adolescents in the United
States (see
http://www.cdc.gov/diabetes/projects/diab_children.htm).
The youth population being studied in 8 locations
throughout the United States—more than 5 million, or 6
percent, of all American children younger than 20
years—is not nationally representative. However, the
SEARCH sites were selected for their ability to reach
minority populations, making this study group the
largest and most racially and geographically diverse
group ever involved in a youth diabetes study. It
entails ascertaining new cases of physician-diagnosed
diabetes in noninstitutionalized, civilian people
younger than 20 years of age in 2002–2005: a) in
geographically defined populations in Ohio, Washington,
South Carolina and Colorado; b) among health plan
enrollees in Hawaii (Hawaii Medical Service Association,
Med-Quest, Kaiser Permanente Hawaii) and California
(Kaiser Permanente Southern California excluding San
Diego); and c) among American Indian populations in
Arizona and New Mexico. Race/ethnicity-specific
estimates were pooled across sites using 5
categories: non-Hispanic white (NHW), non-Hispanic black
(NHB), Hispanic (H), Asian-Pacific Islander (API), and
American Indian (AI). The annual total number of new
cases of diabetes in people younger than 20 years of age
was estimated by applying the age-, sex-, and
racial/ethnic group-specific rates of new cases from
SEARCH to the corresponding U.S. resident population.
The data presented in the following table were derived
from the March 2009 Diabetes Care supplement listed in
the footnote to the table below; data for AIs were
provided by the SEARCH Coordinating Center.
Type 1 | Type 2 | |||
---|---|---|---|---|
Rate (per 100,000/year) | 95% CI* | Rate (per 100,000/year) | 95% CI | |
Age 0 – 9 Years |
||||
NHW | 24.8 | (23.5 – 26.1) | 0.2 | (0.1 – 0.4) |
NHB | 15.7 | (13.7 – 17.9) | 1.1 | (0.7 – 1.9) |
H | 14.1 | (12.4 – 16.1) | 0.5 | (0.3 – 1.0) |
API | 6.4 | (4.8 – 8.5) | 0.6 | (0.3 – 1.5) |
AI | 4.2 | (2.4 – 7.5) | 0.4 | (0.1 – 2.2) |
All | 19.7 | (18.8 – 20.6) | 0.4 | (0.3 – 0.6) |
Age 10 – 19 Years |
||||
NHW | 22.6 | (21.4 – 23.8) | 3.7 | (3.2 – 4.2) |
NHB | 15.7 | (13.8 – 17.8) | 19.0 | (16.9 – 21.3) |
H | 13.8 | (12.1 – 15.8) | 11.6 | (10.0 – 13.4) |
API | 7.4 | (5.8 – 9.6) | 12.1 | (9.9 – 14.8) |
AI | 4.7 | (2.8 – 7.8) | 32.0 | (26.2 – 39.0) |
All | 18.6 | (17.8 – 19.4) | 8.5 | (8.0 – 9.1) |
*Confidence interval
References:
The SEARCH for Diabetes in Youth Study Group. The many
faces of diabetes in American youth: type 1 and type 2
diabetes in five race and ethnic populations.
Diabetes Care 2009;32(Suppl 2):S99–S147.
Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, D'Agostino RB Jr, Imperatore G, Johansen JM, Linder B, Liu LL, Loots B, Marcovina S, Mayer-Davis EJ, Pettitt DJ, Waitzfelder B. Incidence of diabetes in youth in the United States. JAMA 2007;297:2716–2724.
SEARCH Study Group. SEARCH for Diabetes in Youth: a multicenter study of the prevalence, incidence and classification of diabetes mellitus in youth. Control Clin Trials 2004;25:458–471.
Prediabetes among people aged 20 years or older, United States, 2010
Data sources:
2005–2008 National Health and Nutrition Examination
Survey (NHANES), National Center for Health Statistics,
Centers for Disease Control and Prevention. Available at
http://www.cdc.gov/nchs/nhanes.htm.
U.S. Census Bureau, resident population estimates for 10/1/2010. Available at http://2010.census.gov/news/releases/operations/cb10-cn93.html.
Methods:
With the exception of American Indians, the percentage
of people aged 20 years or older with prediabetes was
estimated using the fasting subsample from the 2005–2008
NHANES data. People without diabetes were classified as
having prediabetes if they had fasting plasma glucose
values of 100 to 125 mg/dL or A1c values of 5.7% to
6.4%. The prediabetes estimate was applied to the 2010
U.S. resident population aged 20 years or older to
derive the number of adults with prediabetes. We used
both fasting glucose and A1c levels to define
prediabetes because these are the tests most frequently
used in clinical settings. These tests have limitations
in identifying populations with prediabetes and the
implications of the age and race differences between
groups in the prediabetes estimates are not known.
Research is ongoing to ascertain the best use of
laboratory blood tests to detect people who may have
prediabetes (see the National Glycosylated
Standardization Program at
http://www.ngsp.org/CAC2009.asp) and to improve the
understanding of who has prediabetes.
References:
Personal communication from B. V. Howard, MD, MedStar
Research Institute, Hyattsville, MD, concerning
unpublished data from the Strong Heart Study on the
estimated age-adjusted percentage of American Indians
aged 15 years or older with impaired fasting glucose.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2011;34(Suppl. 1):S66–S68. Available at http://care.diabetesjournals.org/content/34/Supplement_1/S62.full.pdf+html.
Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233–240.
Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW; Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;10:1845–1850.
Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, Kuller LH, Kronmal RA, Resnick HE, Psaty BM. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. Arch Intern Med 2002;62:209–216.
Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800–811.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–1789.
Gestational diabetes in the United States
References:
Hunt KJ, Schuller KL. The increasing prevalence of
diabetes in pregnancy. Obstet Gynecol Clin North Am
2007;34:173–199.
Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care 30 Suppl 2:S141−S146, 2007. Erratum in: Diabetes Care 2007;30(12):3154.
International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, Leiva A, Hod M, Kitzmiler JL, Lowe LP, McIntyre HD, Oats JJ, Omori Y, Schmidt MI. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33(3):676–682.
Coustan DR, Lowe LP, Metzger BE, Dyer AR. International Association of Diabetes and Pregnancy Study Groups. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol 2010;202(6):654.e1–654.e6.
Kitzmiller JL, Dang-Kilduff L, Taslimi MM. Gestational diabetes after delivery: short-term management and long-term risks. Diabetes Care 2007;30:S225–S235.
Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862−1868.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2011;34(Suppl. 1):S68. Available at http://care.diabetesjournals.org/content/34/Supplement_1/S62.full.pdf+htmll.
Treatment of diabetes in the United States, 2007–2009
Data source:
2007–2009 National Health Interview Survey (NHIS),
National Center for Health Statistics, Centers for
Disease Control and Prevention. Available at
http://www.cdc.gov/nchs/nhis.htm.
Methods:
The distribution percentage of treatment type among
civilian, noninstitutionalized adults aged 18 years or
older with diagnosed diabetes was calculated using the
following treatment questions from the 2007–2009 NHIS:
“Are you now taking insulin?” “Are you now taking
diabetic pills to lower your blood sugar?”
Deaths among people with diabetes, United States, 2007
Data source:
The number of deaths with diabetes as any-listed cause
of death among U.S. residents was obtained from the
multiple cause-of-death dataset, National Center for
Health Statistics, Centers for Disease Control and
Prevention, using the Tenth Revision of the
International Classification of Diseases cause-of-death
codes E10–E14.
References:
Xu JQ, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths:
Final data for 2007. National Vital Statistics Reports
2010;58(19). Available at
http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_19.pdf [PDF – 3.4MB].
McEwen LN, Kim C, Haan M, Ghosh D, Lantz PM, Mangione CM, Safford MM, Marrero D, Thompson TJ, Herman WH; TRIAD Study Group. Diabetes reporting as a cause of death: results from the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 2006;29:247–253.
Saydah SH, Geiss LS, Tierney E, Benjamin SM, Engelgau M, Brancati F. Review of the performance of methods to identify diabetes cases among vital statistics, administrative, and survey data. Ann Epidemiol 2004;14:507–516.
Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care 1998;21:1138–1145.
Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001;161:1717–1723.
Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007;147:149–155.
Estimated diabetes costs in the United States, 2007
Reference:
American Diabetes Association. Economic Costs of
Diabetes in the United States in 2007. Diabetes Care
2008;31:596–615.
The estimated costs of diabetes in the United States were based on a study by the Lewin Group, Inc., for the American Diabetes Association and are 2007 estimates of both the direct (cost of medical care and services) and indirect costs (costs of short-term and permanent disability and of premature death) attributable to diabetes. This study used a specific cost-of-disease methodology to estimate the health care costs due to diabetes.
Complications of diabetes in the United States
Heart disease and stroke
Reference:
Gorina Y, Lentzer H. Multiple Causes of Death in
Old Age. Hyattsville: Aging Trends, No.9. National
Center for Health Statistics, CDC; 2008. Available at
http://www.cdc.gov/nchs/data/ahcd/agingtrends/09causes.pdf [PDF–618KB].
Tables 1–2 in the above reference provide the data for the bullets on heart disease and stroke. A total of 174,130 death certificates in 2004 mentioned diabetes as a cause of death among people aged 65 years or older (Table 1). Among these 174,130 deaths, 117,810 (68%) also mentioned heart disease as a cause of death and 27,874 (16%) mentioned stroke (Table 2).
Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: National Diabetes Data Group, editors. Diabetes in America, 2nd ed. Washington, DC: U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995. NIH Publication No. 95-1468. p. 233–257.
Kuller LH. Stroke and diabetes. In: National Diabetes
Data Group, editors. Diabetes in America, 2nd ed.
Washington, DC: U.S. Department of Health and Human
Services, National Institutes of Health, National
Institute of Diabetes and Digestive and Kidney Diseases,
1995. NIH Publication No. 95-1468. p. 449–456.
Hypertension
Data source:
2005–2008 National Health and Nutrition Examination
Survey (NHANES), National Center for Health Statistics,
Centers for Disease Control and Prevention. Available at
http://www.cdc.gov/nchs/nhanes.htm.
Methods:
The percentage of adults aged 20 years or older with
self-reported diabetes that have hypertension was
estimated based on blood pressure greater than or equal
to 140/90 millimeters of mercury or current use of
prescription medication for hypertension.
Blindness and eye problems
References:
Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss
LS, Gregg EW, Albright AL, Klein BEK, Klein R.
Prevalence of diabetic retinopathy in the United States,
2005−2008. JAMA 2010;304(6):649−656.
Klein R, Klein BEK. Vision disorders in diabetes. In: National Diabetes Data Group, editors, Diabetes in America, 2nd ed. Washington, DC: U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995. NIH Publication No. 95-1468:293–336.
Kidney disease
Data source:
United States Renal Data System, Renal Data Extraction
and Referencing System [online data querying
application]. 2010 Annual Data Report dataset. Available
at
http://www.usrds.org/odr/xrender_home.asp. Accessed
December 9, 2010.
Nervous system disease
References:
Eastman RC. Neuropathy in diabetes. In: National
Diabetes Data Group, editors. Diabetes in America, 2nd
ed. Washington, DC: U.S. Department of Health and Human
Services, National Institutes of Health, National
Institute of Diabetes and Digestive and Kidney Diseases,
1995. NIH Publication No. 95-1468:339–348.
Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, Burt V, Curtin L, Engelgau M, Geiss L. Prevalence of lower-extremity disease in the US adult population ≥40 years of age with and without diabetes: 1999–2000 National Health and Nutrition Examination Survey. Diabetes Care 2004;27:1591–1597.
Amputations
Data source:
Centers for Disease Control and Prevention. National
Diabetes Surveillance System. Available at
http://www.cdc.gov/diabetes/statistics/index.htm.
Reference:
Li Y, Burrows N, Gregg E, Geiss L. Declining Trends in
Hospitalizations for Non-traumatic Lower Extremity
Amputation in the Diabetic Population—United States,
1988–2006 [abstract]. Presented during the 70th
Scientific Sessions of the American Diabetes
Association. June 2010.
Dental disease
References:
Tsai C, Hayes C, Taylor GW. Glycemic control of type 2
diabetes and severe periodontal disease in the US adult
population. Community Dent Oral Epidemiol
2002;30:182–192.
Personal communication from R. H. Selwitz, DDS, National Institute of Dental and Craniofacial Research, Bethesda, MD [retired], concerning unpublished data from the third National Health and Nutrition Examination Survey, 1988–1994.
Complications of pregnancy
References:
Personal communication from T. A. Buchanan, MD,
Professor of Medicine, Obstetrics and Gynecology, and
Physiology and Biophysics, USC Keck School of Medicine,
Los Angeles, CA.
Coustan DR. Gestational diabetes. Diabetes Care 1993;16(3):8–15.
Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD. Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA 1991;265:731–736.
Other complications
References:
Fishbein H, Palumbo PJ. Acute metabolic complications in
diabetes. In: National Diabetes Data Group, editors.
Diabetes in America, 2nd ed. Washington, DC: U.S.
Department of Health and Human Services, National
Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases. NIH Publication No.
95-1468:283–291, 1995.
Valdez R, Narayan KM, Geiss LS, Engelgau MM. Impact of diabetes mellitus on mortality associated with pneumonia and influenza among non-Hispanic black and white US adults. Am J Public Health 1999;89:1715–1721.
Gregg EW, Beckles GL, Williamson DF, Leveille SG, Langlois JA, Engelgau MM, Narayan KM. Diabetes and physical disability among older U.S. adults. Diabetes Care 2000;23:1272–1277.
Sinclair AJ, Conroy SP, Bayer AJ. Impact of diabetes on physical function in older people. Diabetes Care 2008;31:233–235.
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069−1078.
González JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ, Safren SA. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 2008;31:2398–2403.
Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008;31:2383–2390.
Egede LE, Ellis C. Diabetes and depression: global perspectives. Diabetes Res Clin Pract 2010;87:302–312.
Preventing diabetes complications
Glucose control
References:
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE,
Cull CA, Hadden D, Turner RC, Holman RR. Association of
glycaemia with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 35): prospective
observational study. BMJ 2000;321(7258):405–412.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653.
Blood pressure control
References:
Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB,
Black H, Camel G, Davis BR, Frost PH, Gonzalez N,
Guthrie G, Oberman A, Rutan GH, Stamler J. Effect of
diuretic-based antihypertensive treatment on
cardiovascular disease risk in older diabetic patients
with isolated systolic hypertension. Systolic
Hypertension in the Elderly Program Cooperative Research
Group. JAMA 1996;276:1886–1892.
Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–1762.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998;317:713–720.
Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412–419.
Control of blood lipids
References:
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444
patients with coronary heart disease: the Scandinavian
Simvastatin Survival Study (4S). Lancet
1994;344:1383–1389.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–1622.,
Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998;97:1446–1452.
Preventive care practices for eyes, feet, and kidneys
References:
Ferris FL 3rd. How effective are treatments for diabetic
retinopathy? JAMA 1993;269:1290–1291.
Zhang X, Gregg EW, Cheng YJ, Thompson TJ, Geiss LS,
Dueñas MR, Saaddine JB.
Diabetes mellitus and visual impairment: national health
and nutrition examination survey, 1999–2004. Arch
Ophthalmol 2008;126:1421–1427.
Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA. Lower-extremity amputation in people with diabetes. Epidemiology and prevention. Diabetes Care 1989;12:24–31.
Litzelman DK, Slemenda CW, Langefeld CD, Hays LM, Welch MA, Bild DE, Ford ES, Vinicor F. Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1993;119:36–41.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878.
Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910–912.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456–1462.
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30–48.
What is diabetes?
References:
The Expert Committee on the Diagnosis and Classification
of Diabetes Mellitus. Report of the Expert Committee on
the Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care 2011;34(Suppl. 1):S62–S66.
Available at
http://care.diabetesjournals.org/content/34/Supplement_1/S62.full.pdf+html.
Dall TM, Mann SE, Zhang Y, Quick WW, Seifert RF, Martin J, Huang EA, Zhang S. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Population Health Management 2009;12:103–110.
Johnson JA, Pohar SL, Majumdar SR. Health care use and costs in the decade after identification of type 1 and type 2 diabetes: a population-based study. Diabetes Care 2006;29:2403–2408.
Ng E, Dasgupta K, Johnson JA. An algorithm to differentiate diabetic respondents in the Canadian Community Health Survey. Health Rep 2008;19:71–79.
Coustan DR. Gestational diabetes. Diabetes Care 1993;16(3):8–15.
Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD. Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA 1991;265:731–736.
Prevention or delay of type 2 diabetes
References:
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF,
Lachin JM, Walker EA, Nathan DM; Diabetes Prevention
Program Research Group. Reduction in the incidence of
type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med 2002;346:393–403.
Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677–1686.
The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care 2003;26:36–47.
Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003;26:2518–2523.
Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323–332.
Contact Us:
- CDC Diabetes Public Inquiries
- 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348
8am-8pm ET
Monday-Friday
Closed Holidays - cdcinfo@cdc.gov